Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Price:
28.12
CNY
3%
Market Closed
Market Cap:
¥11.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
|
CN |
|
Next Geosolutions Europe SpA
MIL:NXT
|
IT |
|
T
|
Tanla Platforms Ltd
NSE:TANLA
|
IN |
|
P
|
Pilani Investment And Industries Corporation Ltd
NSE:PILANIINVS
|
IN |
|
Ishizuka Glass Co Ltd
TSE:5204
|
JP |
|
BioNTech SE
NASDAQ:BNTX
|
DE |
|
Danone SA
PAR:BN
|
FR |
|
B
|
Bed Bath & Beyond Inc
LSE:0HMI
|
US |
|
K
|
Kuraray Co Ltd
SWB:KUY
|
JP |
|
Sumitomo Realty & Development Co Ltd
TSE:8830
|
JP |
|
J
|
Japan Metropolitan Fund Investment Corp
TSE:8953
|
JP |
|
Kodiak Copper Corp
XTSX:KDK
|
CA |
Relative Value
The Relative Value of one
Chengdu Olymvax Biopharmaceuticals Inc
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 28.12 CNY,
Chengdu Olymvax Biopharmaceuticals Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Chengdu Olymvax Biopharmaceuticals Inc Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Chengdu Olymvax Biopharmaceuticals Inc Competitors
Chengdu Olymvax Biopharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
|
11.4B CNY | 16.1 | 177.8 | 132.5 | 132.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.8B USD | 5.9 | 86.7 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.8B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.4B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD | 9.5 | 28.8 | 21.7 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.4B USD | 5.5 | 17.4 | 12.8 | 14.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
35.7B EUR | 10.3 | 33.1 | 35.7 | 36.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
